Send this to a friend

RXi scarring treatment trial yields positive results

RXi Pharmaceuticals, a clinical-stage drug company based in Marlborough, on Monday announced positive results from a clinical trial of its lead drug candidate, RXI-109, a compound designed to reduce hypertrophic scarring after surgery and traumatic injury.
According to a company statement, scars treated in the Phase 2 clinical trial showed statistically-significant improvement in appearance following scar revision surgery, and treatment with RXI-10 ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media